Atea Pharmaceuticals is a biopharmaceutical company developing oral medications to treat viral infections. The company's primary program combines two drug candidates—bemnifosbuvir and ruzasvir—currently in Phase 3 testing for hepatitis C, while also pursuing AT-587 in earlier-stage trials for chronic hepatitis E infection. Atea operates a proprietary technology platform for creating antiviral compounds and maintains a partnership with MSD International for ruzasvir development.

entry readiness 11 · NOT READY · exit proximity 0

Value area 4.17–5.45 · 35% of 120d volume overhead · moderate overhead